Corbus Pharma

Corbus Pharma Corbus (Nasdaq: CRBP) is connecting innovation to purpose to improve the futures of cancer and obesity patients.

04/08/2026

Updated clinical data from the Phase 1/2 study of CRB-701 in both and has been accepted for presentation at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2 in Chicago. Data will include clinical response durability as well as HNSCC patient subgroup analysis. For details: https://bit.ly/4dsJhBT

04/07/2026

Today is !

At Corbus, we're focused on advancing promising new treatments for and , two of the most urgent health challenges of our time.

Learn more about our work: corbuspharma.com

04/07/2026

"This milestone marks an important transition from clinical proof of concept to pending late-stage registrational development and the potential for regulatory submission of CRB-701." – Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. Read more about our broad alignment with U.S. FDA on the registration path for CRB-701 in second-line and : https://bit.ly/4dsJhBT

04/07/2026

Corbus today announced broad alignment with U.S. Food and Drug Administration on the registration path for CRB-701, the Company's next-generation, highly stable Nectin-4 targeting ADC, in head and neck squamous cell carcinoma (HNSCC) and cervical cancer. The FDA feedback enables Corbus to proceed with its proposed registrational study design and endpoints to support potential accelerated approval in second-line HNSCC and cervical cancer.

For details: https://bit.ly/4dsJhBT

04/02/2026

Why does Nectin-4 matter in cancer? Certain solid tumors — including cervical, head & neck and bladder cancers — overexpress Nectin-4, a cell adhesion protein linked to aggressive tumor growth, metastasis, and poorer patient outcomes. Corbus is developing CRB-701 to exploit this overexpression and deliver targeted treatment directly to tumor cells.

Learn more: https://bit.ly/40qrinT

03/25/2026

At Corbus, we are dedicated to developing treatments that aim to significantly improve patient outcomes in cancer care. Learn about our oncology pipeline: https://bit.ly/40qrinT

03/24/2026

Attending the BMO 2026 Metabolic Health Summit? Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in the Emerging Companies Panel: What's Next in the Treatment of Metabolic Disease today, March 24, 2026 at 12:45 pm ET. https://bit.ly/3NDPUGR

03/23/2026

Our CEO, Yuval Cohen Ph.D., will join a panel to discuss CRB-913, an orally delivered highly peripherally restricted CB1 inverse agonist for the treatment of obesity, at the BMO 2026 Metabolic Health Summit tomorrow, March 24th. For event details: https://bit.ly/3NDPUGR

03/18/2026

Save the date - Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a moderated panel discussion at the BMO 2026 Metabolic Health Summit, to be held in New York, NY, on Tuesday, March 24, 2026. For details: https://bit.ly/4uBGRXJ

03/11/2026

Our clinical development is focused on scientifically validated mechanisms that regulate appetite, energy use, and metabolic function. For more on Corbus' therapy pipeline, visit: https://bit.ly/40Lts1n

03/09/2026

"Our encouraging data readouts for CRB-701 and CRB-913 in the fourth quarter of 2025 set the stage for a potentially transformative 2026," said Yuval Cohen, Ph.D., Corbus CEO. Read more for key corporate and program updates: https://bit.ly/47i6aE8

03/09/2026

Corbus today provided a corporate update and reported financial results for the fourth quarter and year ended December 31, 2025. For details: https://bit.ly/47i6aE8

Address

500 River Ridge Drive, Second Floor
Norwood, MA
02062

Opening Hours

Monday 8:30am - 5:30pm
Tuesday 8:30am - 5:30pm
Wednesday 8:30am - 5:30pm
Thursday 8:30am - 5:30pm
Friday 9am - 5:30pm

Telephone

+16179630100

Website

Alerts

Be the first to know and let us send you an email when Corbus Pharma posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Corbus Pharma:

Shortcuts

Featured

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Our Story

Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases by leveraging its industry leading pipeline of endocannabinoid system-targeting drug candidates. The Company's lead product candidate, lenabasum, is a novel, synthetic, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.

Corbus licensed the exclusive worldwide rights to develop, manufacture and market drug candidates from more than 600 novel compounds targeting the endocannabinoid system from Jenrin Discovery LLC. The pipeline includes CRB-4001, a 2nd generation, peripherally-restricted, selective cannabinoid receptor type 1 (CB1) inverse agonist specifically designed to eliminate blood-brain barrier pe*******on and brain CB1 receptor occupancy that mediate the neuropsychiatric issues associated with first-generation CB1 inverse agonists. Potential indications for CRB-4001 include NASH, primary biliary cholangitis, idiopathic pulmonary fibrosis, radiation-induced pulmonary fibrosis, myocardial fibrosis after myocardial infarction and acute interstitial nephritis, among others. CRB-4001 is scheduled to enter a Phase 1 study in 2019 followed a National Institutes of Health (NIH)-funded first-in-patient Phase 2 study.